11.5 C
New York
Wednesday, February 8, 2023

Is TScan Therapeutics Inc. (NASDAQ: TCRX) The Best Stock To Invest In?

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for TScan Therapeutics Inc. (TCRX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.08, or -3.85%, to $2.00. The TScan Therapeutics Inc. has recorded 39,405 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

TScan Therapeutics Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $2.08 and fluctuated between $2.6700 as its day high and $1.9500 as its day low. The current market capitalization of TScan Therapeutics Inc. is $49.63M. A total of 6.07 million shares were traded on the day, compared to an average of 26.68K shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, TCRX has seen 2 BUY and 0 SELL insider trades, representing the acquisition of 6,000 and the disposition of 0 shares. Over the last 12 months, there were 13 BUYs and 0 SELLs from insiders. Insiders purchased 1,405,792 shares during that period but sold 0.

In the most recent transaction, Silver Brian M. bought 3,158 shares of TCRX for 1.56 per share on Dec 28. After the transaction, the Chief Financial Officer now owns 32,885 company shares. In a previous transaction on Dec 27, Silver Brian M. bought 2,842 shares at 1.50 per share. TCRX shares that Chief Financial Officer owns now total 29,727.

Among the insiders who bought shares, SOUTHWELL DAVID P acquired of 25,000 shares on May 18 at a per-share price of $3.59. This resulted in the Chief Executive Officer holding 171,569 shares of TCRX after the transaction. In another insider transaction, BAKER BROS. ADVISORS LP bought 25,865 shares at $1.99 per share on May 11. Company shares held by the Director now total 2,528,583.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for TCRX in the last 3 months, the mean price target is $14.00 with high estimates of $21.00 and low estimates of $6.00. In terms of 52-week highs and lows, TCRX has a high of $5.60 and a low of $1.45.

As of this writing, TCRX has an earnings estimate of -$0.72 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.65 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.67 in the last quarter, which was 6.90% higher than expectations of -$0.72.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TCRX is Overweight with a score of 5.00. A total of 4 analysts rated the stock as Buy while 1 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles